CVR 16406899Public limited company (A/S)Engroshandel med medicinalvarer og sygeplejeartikler (464610)Vallensbæk StrandFounded 2 Jan 1984
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about TAKEDA PHARMA A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
68
CVR, Aug 2026
-5 (-6.8%) over 12 months
Revenue
1.1B
DKK, annual report 2026
+0.9% on 2025
Result
+88.6M
DKK, annual report 2026
Equity
456.5M
DKK, annual report 2026
Takeda Pharmaceuticals International AG100% of capital and votes
Operating company
Dandex estimate: 68 employees registered in 2026Enor Cerimagicsince 17 Aug 2026
Owners of 5% or more. CVR registers shares in bands, not exact figures.
100% of capital and votessince 15 Feb 2019
CVR 28313519100% of capital and votesnotified 15 Feb 201930 Sep 2011 to 15 Feb 2019
TAKEDA PHARMA A/S holds no Danish company now.
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR.
CVR 14802398100% of capital and votes9 Jun 2015 to 30 Aug 2016
CVR 26895553100% of capital and votes17 Feb 2015 to 29 Jun 2015
CVR 26812305100% of capital and votes17 Feb 2015 to 29 Jun 2015
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Showing 50 of 76 former officers.
Showing 25 of 76. The list above has every one.
Aug 2026, monthly: 68 employees, 65 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 391 | 527 | 485 | 529 | 584 | 665 | 640 | 664 | 657 | 688 | 694 | 703 | 693 | No count | No count | No count | No count | 502 | 549 | 544 | 322 | 284 | 277 | 268 | 263 | 257 | 257 | 257 | 259 | 259 | 261 | 251 | 253 | 250 | 250 | 249 | 242 | 235 | 241 | 237 | 238 | 232 | 228 | 238 | 231 | 224 | 223 | 224 | 224 | 229 | 244 | 238 | 225 | 228 | 235 | 238 | 229 | 226 | 226 | 219 | 227 | 220 | 234 | 214 | 216 | 220 | 217 | 213 | 204 | 200 | 192 | 191 | 187 | 214 | 191 | 183 | 184 | 177 | 196 | 169 | 163 | 157 | 160 | 161 | 165 | 161 | 176 | 160 | 164 | 165 | 169 | 165 | 167 | 162 | 163 | 168 | 92 | 82 | 98 | 78 | 83 | 85 | 82 | 96 | 100 | 78 | 75 | 81 | 83 | 82 | 84 | 85 | 80 | 80 | 80 | 84 | 78 | 76 | 81 | 81 | 74 | 76 | 78 | 86 | 73 | 73 | 74 | 80 | 80 | 72 | 71 | 76 | 78 | 78 | 74 | 85 | 75 | 75 | 78 | 87 | 78 | 80 | 82 | 83 | 88 | 81 | 82 | 82 | 73 | 77 | 79 | 73 | 78 | 72 | 78 | 73 | 85 | 80 | 86 | 79 | 68 |
| FTE | 369 | 518 | 477 | 489 | 553 | 623 | 628 | 627 | 647 | 682 | 686 | 714 | 724 | 611 | 576 | 549 | 530 | 498 | 541 | 556 | 410 | 272 | 267 | 262 | 255 | 250 | 249 | 251 | 251 | 251 | 253 | 245 | 245 | 243 | 240 | 234 | 233 | 229 | 228 | 225 | 226 | 223 | 220 | 223 | 220 | 216 | 216 | 214 | 215 | 217 | 222 | 219 | 214 | 217 | 217 | 217 | 218 | 215 | 213 | 209 | 212 | 209 | 210 | 207 | 205 | 206 | 203 | 200 | 195 | 193 | 185 | 184 | 183 | 187 | 183 | 172 | 173 | 169 | 164 | 161 | 158 | 148 | 152 | 151 | 166 | 157 | 164 | 153 | 155 | 157 | 160 | 159 | 159 | 159 | 156 | 157 | 83 | 79 | 84 | 77 | 80 | 79 | 76 | 81 | 84 | 76 | 71 | 69 | 70 | 70 | 75 | 71 | 72 | 73 | 74 | 73 | 72 | 70 | 71 | 70 | 68 | 69 | 73 | 72 | 67 | 69 | 68 | 67 | 70 | 65 | 66 | 65 | 66 | 67 | 69 | 69 | 68 | 69 | 69 | 71 | 71 | 71 | 71 | 71 | 71 | 70 | 72 | 71 | 69 | 67 | 69 | 68 | 68 | 68 | 68 | 66 | 68 | 68 | 68 | 66 | 65 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2026, DKK: Revenue 1.1B, Gross profit 215.7M, Operating profit 113M, Result for the year 88.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2026, DKK: Total assets 623.5M, Equity 456.5M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | 910,058 | 1,061,206 | 1,118,710 | 1,102,419 | 1,112,753 |
| Gross profit | Not reported | Not reported | 437,703 | Not reported | 215,662 |
| Operating profit | +41,266 | +20,842 | +337,589 | +17,248 | +113,012 |
| Result for the year | +31,795 | +13,573 | +261,222 | +12,162 | +88,641 |
| Equity | 81,238 | 94,892 | 355,951 | 368,294 | 456,501 |
| Total assets | 622,293 | 485,750 | 582,370 | 581,334 | 623,480 |
| Employees (average) | 73 | 70 | 68 | 68 | 68 |
| Credit metrics (Dandex calculations) | |||||
| Revenue growth (omsætningsvækst) | -53.1% | 16.6% | 5.4% | -1.5% | 0.9% |
| EBIT margin (overskudsgrad) | 4.5% | 2% | 30.2% | 1.6% | 10.2% |
| EBITDA | 49,530 | 27,436 | 346,095 | 22,830 | 118,342 |
| EBITDA margin (EBITDA-margin) | 5.4% | 2.6% | 30.9% | 2.1% | 10.6% |
| Employee growth (vækst i antal ansatte) | -53.8% | -4.1% | -2.9% | 0% | 0% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 2,829note 1 | 4,701note 1 | 5,201note 1 | 3,166note 1 | 946note 2 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions.
How each credit metric is calculated:
Annual report 2026
1 Apr 2025 to 31 Mar 2026, published 18 Sep 2026
Annual report 2025
1 Apr 2024 to 31 Mar 2025, published 16 Sep 2025
Annual report 2024
1 Apr 2023 to 31 Mar 2024, published 11 Sep 2024
Annual report 2023
1 Apr 2022 to 31 Mar 2023, published 29 Sep 2023
Annual report 2022
1 Apr 2021 to 31 Mar 2022, published 28 Sep 2022
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for TAKEDA PHARMA A/S:
Have Pro? Sign in.
Amounts in DKK. Cash price is per DKK 1 of nominal capital, which a share split does not move. Implied value is the whole capital after the step at its cash price, not a valuation.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseMergerPaid in 62,820,180 | None | 62,820,180 | None | 10,100,000 | |
| DecreaseMoved to a reserve | None | None | None | 10,000,000 | |
| IncreaseContribution in kindPaid in 29,652,716,800 | None | 29,652,716,800 | None | 956,100,000 | |
| IncreaseContribution in kindPaid in 638,596,000 | None | 638,596,000 | None | 810,100,000 | |
| IncreaseContribution in kindPaid in 1,853,178,600 | None | 1,853,178,600 | None | 810,000,000 | |
| IncreaseCashPaid in 1,545,939,200, cash price 1,545.94, implied value 1,250,664,812,800 | 1,545.94 | 1,545,939,200 | 1,250,664,812,800 | 809,000,000 | |
| IncreaseContribution in kindPaid in 671,460,900 | None | 671,460,900 | None | 808,000,000 | |
| IncreaseContribution in kindPaid in 1,418,416,700 | None | 1,418,416,700 | None | 807,000,000 |
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseContribution in kindPaid in 3,053,037,200 | None | 3,053,037,200 | None | 806,000,000 | |
| IncreaseContribution in kindPaid in 28,790,000 | None | 28,790,000 | None | 804,000,000 | |
| IncreaseContribution in kindPaid in 5,249,460,000 | None | 5,249,460,000 | None | 803,000,000 | |
| IncreaseContribution in kindPaid in 19,481,620,000 | None | 19,481,620,000 | None | 802,000,000 | |
| IncreaseContribution in kindPaid in 183,982,600 | None | 183,982,600 | None | 801,000,000 | |
| IncreaseCashPaid in 780,000,000 | None | 780,000,000 | None | 800,000,000 | |
| FoundingNot read from the announcement | None | None | None | 20,000,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Demerger (spaltning), as the demerged company (indskydende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 17 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 17 Nov 2026.
The newest 50 of 120 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Bestyrelse:
Fratrådte:
Gitte Hjelvang, den 17.08.2026, Christian Ramskov, (formand), den 17.08.2026, Koki Sato, den 17.08.2026.
Tiltrådte:
Enor Cerimagic, den 17.08.2026, Malene Kelstrup, den 17.08.2026, Koki Sato, (formand), den 17.08.2026.
Direktion:
Vedtægter ændret: 27.04.2026
Nye binavne: Takeda A/S, Nycomed A/S
Bestyrelse:
Fratrådte:
Christian Ramskov, den 17.04.2026, Koki Sato, (formand), den 17.04.2026.
Tiltrådte:
Christian Ramskov, (formand), den 17.04.2026, Koki Sato, den 17.04.2026.
Direktion:
Direktion:
Fratrådte:
Christian Ramskov, (adm. dir), den 01.09.2025.
Tiltrådte:
Georgios Faidon Kalomoiris, den 01.09.2025.
Direktion:
Fratrådte:
Roland Kurney, (adm. dir), den 01.04.2025.
Tiltrådte:
Christian Ramskov, (adm. dir), den 01.04.2025.
Bestyrelse:
Fratrådte:
Vatroslav Mateljic, (formand), den 28.08.2024.
Tiltrådte:
Koki Sato, (formand), den 28.08.2024.
Vedtægter ændret: 25.04.2023
Bestyrelse:
Fratrådte:
Duarte Joao Lourinho Marchand, (formand), den 31.03.2023.
Tiltrådte:
Vatroslav Mateljic, (formand), den 31.03.2023.
Direktion:
Fratrådte:
Lars Patrik Mikael Forsell, (adm. dir), den 30.09.2021.
Tiltrådte:
Roland Kurney, (adm. dir), den 01.10.2021.
Bestyrelse:
Fratrådte:
Niels Hansen, den 21.05.2021, Athinagoras Efthymios Giannoulis, den 21.05.2021, Ingeborg Rossebø Borgheim, (formand), den 21.05.2021.
Tiltrådte:
Gitte Hjelvang, den 21.05.2021, Christian Ramskov, den 21.05.2021, Duarte Joao Lourinho Marchand, (formand), den 21.05.2021.
Bestyrelse:
Valgt af medarbejderne i virksomheden:
Fratrådte:
Bjarne Mejlstrup Lange, den 01.04.2021.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning.
Aktiver og gæld er overdraget til CVR-nummer: 41059044 Dalmore Invest (Denmark) ApS.
Erhvervsstyrelsen har modtaget spaltningsplan for den påtænkte spaltning af CVR-nummer: 16406899 TAKEDA PHARMA A/S (indskydende fortsættende), der tillige driver virksomhed under navnene NYCOMED DANMARK A/S, DAK LABORATORIES A/S, NYCOMED DAK A/S, NYCOMED DK A/S, BENZON BIOSYSTEMS A/S, BENZON PHARMA A/S, BENZON BIO-TECH A/S, NYCOMED PHARMA A/S, BASODERM A/S, NYCOMED PHARMA-MEDICA A/S, PHARMA-MEDICA A/S, AB PHARMA A/S, DANIMED A/S, NYCOMED BENZON A/S, TAKEDA PHARMACEUTICALS DENMARK A/S, Nettopharma A/S, Pharmachemie A/S, Nycomed Consumer A/S, Shire Denmark A/S og CVR-nummer: 41059044 Dalmore Invest (Denmark) ApS (modtagende).
Erhvervsstyrelsen har modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 16406899 TAKEDA PHARMA A/S og CVR-nummer: 41059044 Dalmore Invest (Denmark) ApS må antages at være tilstrækkeligt sikrede efter spaltningen.
Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående fusion.
Virksomheden er fusioneret med CVR-nummer: 36392290 Shire Denmark A/S, der samtidigt er opløst.
Vedtægter ændret: 01.04.2020
Nyt binavn: Shire Denmark A/S
Kapitalforhøjelsen er besluttet den 01.04.2020.
kr. 100.000,00, indbetalt ved fusion, kurs 62.820,18.
Kapitalen udgør herefter kr. 10.100.000,00.
Ny adresse: Delta Park 45, 2665 Vallensbæk Strand
Ny kommune: Vallensbæk
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 16406899 TAKEDA PHARMA A/S (fortsættende), der tillige driver virksomhed under navnene NYCOMED DANMARK A/S, DAK LABORATORIES A/S, NYCOMED DAK A/S, NYCOMED DK A/S, BENZON BIOSYSTEMS A/S, BENZON PHARMA A/S, BENZON BIO-TECH A/S, NYCOMED PHARMA A/S, BASODERM A/S, NYCOMED PHARMA-MEDICA A/S, PHARMA-MEDICA A/S, AB PHARMA A/S, DANIMED A/S, NYCOMED BENZON A/S, TAKEDA PHARMACEUTICALS DENMARK A/S, Nettopharma A/S, Pharmachemie A/S, Nycomed Consumer A/S og CVR-nummer: 36392290 Shire Denmark A/S (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 16406899 TAKEDA PHARMA A/S og CVR-nummer: 36392290 Shire Denmark A/S må antages at være tilstrækkeligt sikrede efter fusionen.
Bestyrelse:
Valgt af medarbejderne i virksomheden:
Fratrådte:
Marianne Hauge, den 13.08.2019.
Tiltrådte:
Jesper Lindahl, den 13.08.2019.
Suppleanter for valgt af medarbejderne i virksomheden:
Fratrådte:
Jesper Lindahl, den 13.08.2019.
Vedtægterne er yderligere ændret
Vedtægter ændret: 25.02.2019
Vedtægter ændret: 25.02.2019
Kapitalnedsættelse besluttet 25.02.2019 er gennemført 30.03.2019.
Kapitalen udgør herefter kr. 10.000.000,00.
Kapitalnedsættelse besluttet 25.02.2019 henlæggelse til særlig reserve kr. 946.100.000,00 til kurs 100,00.
Virksomhedens kreditorer opfordres til at indberette deres krav til virksomheden. Kreditorerne kan kræve betryggende sikkerhed for uforfaldne krav og betaling af forfaldne krav. Krav skal indberettes senest 4 uger fra dags dato.
Bestyrelse:
Fratrådte:
Ghita Astrup, den 20.12.2017.
Tiltrådte:
Athinagoras Efthymios Giannoulis, den 20.12.2017.
Direktion:
Fratrådte:
Christian Ramskov (adm. dir), den 20.11.2017.
Tiltrådte:
Lars Patrik Mikael Forsell (adm. dir), den 20.11.2017.
Direktion:
Fratrådte:
Ghita Astrup (adm. dir), den 30.09.2017.
Tiltrådte:
Christian Ramskov (adm. dir), den 01.10.2017.
Bestyrelse:
Valgt af medarbejderne i virksomheden:
Suppleanter for valgt af medarbejderne i virksomheden:
Fratrådte:
Marianne Jacobsen, den 16.08.2017.
Bestyrelse:
Fratrådte:
Jean Luc Delay (formand), den 11.05.2017.
Tiltrådte:
Ingeborg Rossebø Borgheim (formand), den 11.05.2017.
Vedtægter ændret: 30.08.2016
Nye binavne: Nettopharma A/S, Pharmachemie A/S, Nycomed Consumer A/S
Vedtægter ændret: 16.03.2016
Kapitalforhøjelse: kr. 146.000.000,00, indbetalt i værdier, kurs 20.310,08.
Kapitalen udgør herefter kr. 956.100.000,00.
Kapitalen er opdelt i klasser.
Vedtægter ændret: 09.03.2016
Bestyrelse:
Fratrådte:
Dennis-Oliver Lauth (formand), den 09.03.2016.
Tiltrådte:
Jean Luc Delay (formand), den 09.03.2016.
CVR-nummer:
16406899.
NAVN:
TAKEDA PHARMA A/S.
Adresse: Dybendal Alle 10, 2630 Taastrup.
Kommune: Høje-Taastrup.
I forbindelse med registreringen den 30.11.2012 blev der ved en fejl ikke offenliggjort ny tegningsregel: Selskabets tegningsregel er: Selskabet tegnes af en direktør, af tre medlemmer af bestyrelsen i forening, af bestyrelsens formand og et andet medlem af bestyrelsen i forening eller af den samlede bestyrelse. .
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem TAKEDA PHARMA A/S, CVR-nr. 16406899 (fortsættende) og ApS KBIL 38 NR. 2505, CVR-nr. 26895553 (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i TAKEDA PHARMA A/S, CVR-nr. 16406899 og ApS KBIL 38 NR. 2505, CVR-nr. 26895553 må antages at være tilstrækkeligt sikrede efter fusionen.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem TAKEDA PHARMA A/S, CVR-nr. 16406899 (fortsættende) og SELSKAB NO 26 81 23 05 ApS, CVR-nr. 26812305 (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i TAKEDA PHARMA A/S, CVR-nr. 16406899 og SELSKAB NO 26 81 23 05 ApS, CVR-nr. 26812305 må antages at være tilstrækkeligt sikrede efter fusionen.
CVR-nummer
16406899.
NAVN:
TAKEDA PHARMA A/S.
Adresse: Dybendal Alle 10, 2630 Taastrup.
Kommune: Høje-Taastrup.
Bestyrelse:
Valgt af medarbejderne i selskabet:
Fratrådte:
Kirsten Betina Kjær Christensen, den 31.03.2015.
Tiltrådte:
Bjarne Mejlstrup Lange, den 31.03.2015.
Suppleanter for valgt af medarbejderne i selskabet:
Fratrådte:
Lise Bredahl Hervik Harre, den 31.03.2015, Bjarne Mejlstrup Lange, den 31.03.2015.
Tiltrådte:
Marianne Jacobsen, den 31.03.2015, Jesper Lindahl, den 31.03.2015.
Bestyrelse:
Udtrådt af bestyrelsen:
Helle Skov, den 06.01.2014.
Indtrådt i bestyrelsen:
Lisbet Rankløve, den 06.01.2014.
Vedtægter ændret:
23.12.2014.
Kapitalforhøjelse:
kr. 100.000,00 indbetalt i værdier, kurs 638.596,00.
Kapitalen udgør herefter kr. 810.100.000,00.
Erhvervsstyrelsen har modtaget fusionsplan
for den påtænkte fusion mellem
CVR-NR. 26812305 SELSKAB NO 26 81 23 05 ApS (ophørende).
CVR-NR. 31885264 PURCHASE VEHICLE OF NOVEMBER 10, 2008 ApS (ophørende).
CVR-NR. 26895553 ApS KBIL 38 NR. 2505 (ophørende).
CVR-NR. 16406899 TAKEDA PHARMA A/S (fortsættende), der tillige driver virksomhed under navnene NYCOMED DANMARK A/S, DAK LABORATORIES A/S, NYCOMED DAK A/S, NYCOMED DK A/S, BENZON BIOSYSTEMS A/S, BENZON PHARMA A/S, BENZON BIO-TECH A/S, NYCOMED PHARMA A/S, BASODERM A/S, NYCOMED PHARMA-MEDICA A/S, PHARMA-MEDICA A/S, AB PHARMA A/S, DANIMED A/S, NYCOMED BENZON A/S, TAKEDA PHARMACEUTICALS DENMARK A/S.
Der er endvidere modtaget erklæring fra
vurderingsmændene om, at kreditorerne i
CVR-NR. 26812305 SELSKAB NO 26 81 23 05 ApS.
CVR-NR. 31885264 PURCHASE VEHICLE OF NOVEMBER 10, 2008 ApS.
CVR-NR. 26895553 ApS KBIL 38 NR. 2505.
CVR-NR. 16406899 TAKEDA PHARMA A/S, må
antages at være tilstrækkeligt sikrede efter fusionen.
Valgt af medarbejderne i selskabet:
Suppleanter for valgt af medarbejderne i selskabet:
Fratrådt som suppleant:
1. suppleant: Susanne Munk, den 31.08.2014.
Tiltrådt som suppleant:
Tidligere 2. suppleant, nu 1. suppleant: Lise Bredahl Hervik Harre
Valgt af medarbejderne i selskabet:
Suppleanter for valgt af medarbejderne i selskabet:
Tiltrådt som suppleant:
2. suppleant: Bjarne Mejlstrup Lange, den 31.08.2014.
Ny adresse:
Dybendal Alle 10, 2630 Taastrup.
Ny kommune:
Høje Taastrup.
Bestyrelse:
Tiltrådt som formand:
Dennis-Oliver Lauth, den 20.03.2014.
Udtrådt af bestyrelsen:
Gilbert Wilhelm Rademacher, den 20.03.2014, Dominic Peter Moorhead, den 20.03.2014.
Indtrådt i bestyrelsen:
Ghita Astrup, den 20.03.2014.
Valgt af medarbejderne i selskabet:
Udtrådt af bestyrelsen:
Marianne Jacobsen, den 26.07.2013.
Indtrådt i bestyrelsen:
Kirsten Betina Kjær Christensen, den 26.07.2013.
Suppleanter for valgt af medarbejderne i selskabet:
Fratrådt som suppleant:
Carsten Martini Nielsen, den 26.07.2013, for Marianne Hauge
Tiltrådt som suppleant:
1. suppleant: Susanne Munk, den 26.07.2013, 2. suppleant: Lise Bredahl Hervik Harre, den 26.07.2013.
Bestyrelse:
Udtrådt af bestyrelsen:
Satoru Noguchi, den 27.06.2013.
Indtrådt i bestyrelsen:
Gilbert Wilhelm Rademacher (formand), den 27.06.2013, Dennis-Oliver Lauth, den 27.06.2013.
Nye binavne:
DAK LABORATORIES A/S, NYCOMED DAK A/S, NYCOMED DK A/S, BENZON BIOSYSTEMS A/S, BENZON PHARMA A/S, BENZON BIO-TECH A/S, NYCOMED PHARMA A/S, BASODERM A/S, NYCOMED PHARMA-MEDICA A/S, PHARMA-MEDICA A/S, AB PHARMA A/S, DANIMED A/S, NYCOMED BENZON A/S, TAKEDA PHARMACEUTICALS DENMARK A/S.
Vedtægter ændret:
30.11.2012.
Selskabet er omdannet til et A/S med CVR-nr 16406899.
NAVN: TAKEDA PHARMA A/S.
ADRESSE: Langebjerg 1, 4000 Roskilde.
Kommune:
Roskilde.
Binavn:
DAK LABORATORIES ApS, NYCOMED DAK ApS, NYCOMED DK ApS, BENZON BIOSYSTEMS ApS, BENZON PHARMA ApS, BENZON BIO-TECH ApS, NYCOMED PHARMA ApS, BASODERM ApS, NYCOMED PHARMA-MEDICA ApS, PHARMA-MEDICA ApS, AB PHARMA ApS, DANIMED ApS, NYCOMED BENZON ApS, TAKEDA PHARMACEUTICALS DENMARK ApS, NYCOMED DANMARK A/S.
Kapital kr. 810.000.000,00.
Bestyrelse:
Satoru Noguchi (formand), Dominic Peter Moorhead, Cand pharm Helle Skov.
Valgt af medarbejderne i selskabet:
Cand pharm Marianne Hauge. (Suppleant: Cand. pharm Carsten Martini Nielsen), Marianne Jacobsen.
Direktion:
Ghita Astrup (adm. dir).
Selskabet tegnes af direktøren alene, bestyrelsesformanden alene eller 2 bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Osvald Helmuths Vej 4, postboks 250, 2000 Frederiksberg.
Regnskabsår:
01.04 - 31.03.
Bestyrelse:
Udtrådt af bestyrelsen:
Charles Albert Depasse, den 26.11.2012.
Indtrådt i bestyrelsen:
Cand pharm Helle Skov, den 26.11.2012.
Vedtægter ændret:
08.11.2012.
Kapitalforhøjelse:
kr. 1.000.000,00 indbetalt i værdier, kurs 185.317,86.
Kapitalen udgør herefter kr. 810.000.000,00.
Vedtægter ændret:
17.07.2012.
Regnskabsår ændret til:
01.04 - 31.03.
Omlægningsperiode:
01.01.2012 - 31.03.2012.
P-number 10058089981, 9999 Ukendt
P-number 1003181334Langebjerg 1, 4000 Roskilde
P-number 1025063577Delta Park 45, 2665 Vallensbæk Strand
P-number 1018761579Dybendal Alle 10, 2630 Taastrup
P-number 1012358748Dybendal Alle 10, 2630 Taastrup
P-number 1003181322Rosengade 1, 8500 Grenaa
P-number 1003181309Helseholmen 1, 2650 Hvidovre
P-number 1003181346Apotekerstien 9, 9500 Hobro
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.